The Government Pharmaceutical Organization (GPO) will start the first clinical trial (Phase 1) of its COVID-19 Vaccine in human developed by using egg-based production technology in this upcoming March after animal trial has shown effective and safe efficacy in boosting immune. The industrial scale production will be conducted at GPO’s Vaccine Production Factory at Saraburi Province with approximate production capacity up to 25-30 million doses. It is expected that in 2022, GPO will be able to begin its Rolling Submissions to Thai FDA in parallel with the human trial Phase 3 and shall be ready for public launch after the FDA registration is approved and granted. GPO has extensive experience in Flu vaccines production and plans to produce COVID-19 vaccines, in cooperation with the Faculty of Tropical Medicine of Mahidol University and with support from the US-based Program for Appropriate Technology in Health (PATH), which has provided vaccine precursors for first and second phase studies.